MARKET

IRWD

IRWD

Ironwood Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.06
-1.01
-7.73%
After Hours: 12.06 0 0.00% 16:41 02/14 EST
OPEN
13.07
PREV CLOSE
13.07
HIGH
13.07
LOW
12.00
VOLUME
2.58M
TURNOVER
--
52 WEEK HIGH
14.10
52 WEEK LOW
7.91
MARKET CAP
1.89B
P/E (TTM)
-400.6645
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IRWD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IRWD News

  • Edited Transcript of IRWD earnings conference call or presentation 13-Feb-20 1:30pm GMT
  • Thomson Reuters StreetEvents.4d ago
  • Ironwood Pharmaceuticals, Inc. (IRWD) CEO Mark Mallon on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.4d ago
  • Ironwood Pharmaceuticals EPS beats by $0.07, beats on revenue
  • seekingalpha.4d ago
  • Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Beat Estimates
  • Zacks.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About IRWD

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
More

Webull offers Ironwood Pharmaceuticals, Inc. (IRWD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.